Demographic and health characteristics of 3,4-methylenedioxymethamphetamine users (MDMA, ecstasy)

被引:1
|
作者
Wieckiewicz, Gniewko [1 ]
Danel, Dariusz [2 ]
Piegza, Magdalena [1 ]
Gorczyca, Piotr [1 ]
Pudlo, Robert [1 ]
机构
[1] Slaski Uniwersytet Med Katowicach, Wydzial Nauk Med Zabrze, Katedra & Oddzial Klin Psychiat, Ul Pyskowicka 49, PL-42612 Katowice, Poland
[2] Polish Acad Sci, Inst Immunol & Terapii Doswiadczalnej Ludwika Hir, Poznan, Poland
关键词
HADS; MDMA; GHQ-28; SUBJECTIVE EXPERIENCES; CARE;
D O I
10.12740/PP/OnlineFirst/134317
中图分类号
R749 [精神病学];
学科分类号
100205 ;
摘要
Aim. MDMA is one of the most commonly used drugs in the world. Clinical studies are currently being conducted around the world on the use of this substance in the treatment of PTSD and alcoholism. However, little demographic information is available on users who use the substance for non-medical purposes. The aim of the study was to determine basic demographic and health characteristics with validated tools. Method. The authors prepared an original questionnaire on the demography of MDMA users and combined it with the General Health Questionnaire-28 (GHQ-28) and the Hospital Anxiety and Depression Scale (HADS). The survey was sent to Polish MDMA users via the Internet. Results. 304 responses were received from people over 18 years of age. MDMA is widespread among young adults, in many different places of residence and regardless of gender. The users take MDMA in both pill and crystal form and very rarely test drugs bought from a dealer. Most users feel that MDMA has had a good impact on their lives. Conclusions. MDMA is rarely used as the only psychoactive substance. MDMA users rate their health higher than people using other psychoactive substances.
引用
收藏
页码:1109 / 1130
页数:22
相关论文
共 50 条
  • [32] Hyponatraemic states following 3,4-methylenedioxymethamphetamine (MDMA, 'ecstasy') ingestion
    Hartung, TK
    Schofield, E
    Short, AI
    Parr, MJA
    Henry, JA
    QJM-AN INTERNATIONAL JOURNAL OF MEDICINE, 2002, 95 (07) : 431 - 437
  • [33] Validating the consumption of MDMA (3,4-methylenedioxymethamphetamine) in an examination of the behavioural effects of "ecstasy" amongst recreational users
    Sherlock, K
    Hay, AWM
    Wolff, K
    Conner, M
    ADDICTION RESEARCH, 1999, 7 (01): : 47 - 62
  • [34] Cerebral 1H MRS alterations in recreational 3,4-methylenedioxymethamphetamine (MDMA, "Ecstasy") users
    Chang, L
    Ernst, T
    Grob, CS
    Poland, RE
    JOURNAL OF MAGNETIC RESONANCE IMAGING, 1999, 10 (04) : 521 - 526
  • [35] Depression, impulsiveness, sleep, and memory in past and present polydrug users of 3,4-methylenedioxymethamphetamine (MDMA, ecstasy)
    Lynn Taurah
    Chris Chandler
    Geoff Sanders
    Psychopharmacology, 2014, 231 : 737 - 751
  • [36] Depression, impulsiveness, sleep, and memory in past and present polydrug users of 3,4-methylenedioxymethamphetamine (MDMA, ecstasy)
    Taurah, Lynn
    Chandler, Chris
    Sanders, Geoff
    PSYCHOPHARMACOLOGY, 2014, 231 (04) : 737 - 751
  • [37] 3,4-methylenedioxymethamphetamine (mdma): A review
    O’Leary G.
    Nargiso J.
    Weiss R.D.
    Current Psychiatry Reports, 2001, 3 (6) : 477 - 483
  • [38] A new cause of valvular heart disease: 3,4-methylenedioxymethamphetamine (MDMA, 'ecstasy')
    Montastruc, F.
    Montastruc, G.
    Vigreux, P.
    Bruneval, P.
    Guilbeau-Frocher, C.
    Cron, C.
    Bagheri, H.
    Delisle, B.
    Lapeyre-Mestre, M.
    Pathak, A.
    Montastruc, J. L.
    FUNDAMENTAL & CLINICAL PHARMACOLOGY, 2012, 26 : 10 - 10
  • [39] Valvular heart disease in a patient taking 3,4-methylenedioxymethamphetamine (MDMA, 'Ecstasy')
    Montastruc, Francois
    Montastruc, Guillaume
    Vigreux, Philippe
    Bruneval, Patrick
    Guilbeau-Frugier, Celine
    Cron, Christophe
    Bagheri, Haleh
    Delisle, Bernadette
    Lapeyre-Mestre, Maryse
    Pathak, Atul
    Montastruc, Jean-Louis
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2012, 74 (03) : 547 - 548
  • [40] REVIEW OF THE PHARMACOLOGY AND CLINICAL-PHARMACOLOGY OF 3,4-METHYLENEDIOXYMETHAMPHETAMINE (MDMA OR ECSTASY)
    GREEN, AR
    CROSS, AJ
    GOODWIN, GM
    PSYCHOPHARMACOLOGY, 1995, 119 (03) : 247 - 260